Hair Loss: Finasteride May Raise Risk of Psychiatric Side Effects

A new report in The Journal of Clinical Psychiatry highlights increased concerns regarding finasteride, a hair loss medication, linking its use to a higher risk of depression and suicide, and criticizes original manufacturer Merck and the FDA for inadequate warnings and research. While Organon, the current manufacturer, defends the drug's established safety and efficacy, and other experts call for further study rather than immediate curtailment, the FDA has already added depression (2011) and suicidality (2022) to the drug's label, receiving over 700 related adverse event reports. This development suggests potential for heightened regulatory scrutiny, increased litigation risk, and possible market impact for companies producing finasteride, particularly for its cosmetic indication, as the report's author advocates for suspending its marketing for hair loss.

Analysis

A recent report in The Journal of Clinical Psychiatry has raised significant concerns regarding finasteride, a medication primarily used for hair loss, by linking its use to an increased risk of depression and suicide. The author, Mayer Brezis, criticizes Merck, the original manufacturer, and the FDA for a two-decade delay in recognizing and adequately warning about these neuropsychiatric side effects, based on reviews of adverse event reporting systems and healthcare records from 2017-2023. This commentary suggests a significant increase in mental health risks, even post-discontinuation of the drug.

Organon, the current manufacturer of finasteride, maintains the drug's established safety and efficacy, citing thorough regulatory reviews and continuous post-marketing surveillance. While other medical experts acknowledge the need for further research, they view the report as a commentary rather than definitive scientific study and do not advocate for immediate curtailment of finasteride's use, noting that the 1mg dose for hair loss may be prescribed to a population already prone to psychological issues.

Despite the differing views, the FDA has already updated finasteride's label to include depression (2011) and suicidality (2022) as potential side effects, having received over 700 reports of suicidal thoughts or attempts. This regulatory action, combined with the report's call to suspend marketing for cosmetic purposes, indicates heightened scrutiny on finasteride, particularly for its hair loss indication. The moderately negative sentiment (-0.65) and moderate market impact (0.55) suggest potential for increased regulatory and legal risks for manufacturers.

Key Decisions for Investors

• Investors should closely monitor regulatory actions by the FDA and other health authorities regarding finasteride's labeling and marketing, especially for its cosmetic indication.
• Assess the potential for increased litigation risk and product liability claims against Organon (OGN) and, given historical context, Merck (MRK), which could impact their financial outlook.
• Evaluate the broader implications for companies manufacturing drugs with cosmetic applications, as this report may signal a trend towards stricter scrutiny of long-term neuropsychiatric side effects.